dreamstime_xs_181396495
© Rattana Rueangha

Pharma is “a growth market” for ocean carriers as shippers become cost- and emissions-conscious, but temperature and time-sensitive requirements could mean a liner’s “piece of the pie” will only be a sliver.  

Cathy O’Brien, VP of international sales at UPS Healthcare, told The Loadstar the demand for cold-chain transportation and handling was “growing rapidly”. 

“If we look to the future, more than half of the drugs in development are biologics, which require development in cold chain and temperature monitoring services… the ...

Please Register

To continue reading, please login or register for full access to our free content
Loadstar subscriber
New Loadstar subscriber REGISTER

Comment on this article


You must be logged in to post a comment.
  • Karen Betancourt

    August 06, 2024 at 2:32 pm

    Fascinating place to key an eye on. My concern is whether insurance limits will keep up, as the average biologic is even more expensive per manufacturer WAC than name brands.